Salmen, T.; Bobirca, F.-T.; Bica, I.-C.; Mihai, D.-A.; Pop, C.; Stoian, A.P.
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus. Life 2023, 13, 839.
https://doi.org/10.3390/life13030839
AMA Style
Salmen T, Bobirca F-T, Bica I-C, Mihai D-A, Pop C, Stoian AP.
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus. Life. 2023; 13(3):839.
https://doi.org/10.3390/life13030839
Chicago/Turabian Style
Salmen, Teodor, Florin-Teodor Bobirca, Ioana-Cristina Bica, Doina-Andrada Mihai, Corina Pop, and Anca Pantea Stoian.
2023. "The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus" Life 13, no. 3: 839.
https://doi.org/10.3390/life13030839
APA Style
Salmen, T., Bobirca, F.-T., Bica, I.-C., Mihai, D.-A., Pop, C., & Stoian, A. P.
(2023). The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus. Life, 13(3), 839.
https://doi.org/10.3390/life13030839
